International Journal of
Biotechnology and Molecular Biology Research

  • Abbreviation: Int. J. Biotechnol. Mol. Biol. Res.
  • Language: English
  • ISSN: 2141-2154
  • DOI: 10.5897/IJBMBR
  • Start Year: 2010
  • Published Articles: 100

Short Communication

Authentication of fusion genes in chronic myeloid leukemia

Aamir Rana1,2, Shahzad Bhatti1, Ghulam Muhammad Ali2, Shoukat Ali4, Nazia Rehman3, Sabir Hussain Shah3 and Ammad Ahmad Farooqi1
1Institute of Molecular Biology and Biotechnology, University of Lahore, Pakistan. 2National Institute for Genomics and Advanced Biotechnology, NARC, Islamabad, Pakistan. 3Pakistan Agricultural Research Council (PARC), Institute of Advanced Studies in Agriculture, Islamabad, Pakistan. 4Plant Biotechnology Program, NARC, Islamabad, Pakistan  
Email: [email protected]

  •  Accepted: 30 May 2011
  •  Published: 31 July 2011


Chronic myeloid leukemia is a multifactorial molecular anomaly that confounds the standardization of therapy to date. It is triggered by a broad spectrum of “fused oncoproteins” which are entailed in the disease refractoriness. In Pakistan the molecular diagnosis for leukemia is still in its infancy, as the diagnosis does not efficiently encompass a wide range of the fusion transcripts which are generated as a result of exclusive genomic rearrangements. Two point mutations C944T and T932C of ABL gene were detected which cause complete/partial imatinib resistance with limelight NUP98-LEDGF fusion transcript. It will be helpful in understanding primary resistance of molecularly targeted cancer therapies.

Key words: Allele-specific oligonucleotide polymerase chain reaction (ASO-PCR), leukemia, myeloid, chronic, imatinib.